About Us

Welcome to RESTEM. We are a leading clinical-stage biopharmaceutical company focused on the discovery and development of patient-specific, as well as off-the-shelf and ready-to-use, next-generation cell therapies that are designed to activate and enhance a patient’s own immune system. Our therapies are designed to enable the treatment of a broad range of disabling diseases that improve patient outcomes, as well as overall health and wellness for patients around the world.

RESTEM’s cell therapy platform technology consists of two programs, our umbilical cord lining stem cells (ULSCs), and our natural killer cell (NK) therapeutics. Moreover, we are also developing next-generation cell therapy derivatives based on these two platforms.

Our mission

Our mission is to develop transformative, next-generation cell therapies that have the potential to revolutionize medicine and routine clinical care. We are dedicated to bringing these therapies to patients as rapidly as possible.

learn more

our cells

Our scientists have dedicated decades to groundbreaking research in the study of human cell biology and the development of novel cell therapies that can activate and enhance an individual’s immune system and overall health.

learn more

Our team

RESTEM’s innovative group of accomplished scientists, advisors, and professionals are dedicated to providing the safest and most effective cellular therapies that optimize health, longevity, and wellness to patients around the world.

learn more

Our clinical Trials

We are dedicated to improving health and wellness by enhancing the unique power of the human immune system based on our clinical therapeutic platforms. We have multiple ongoing clinical trials, with several new trials on the horizon. Our current clinical trial program is based on two platform technologies. Our proprietary Umbilical Cord Lining Stem Cell (ULSC) therapy is designed to target serious conditions that include cardiovascular disease, autoimmune disease, and other degenerative diseases. Our NK cell therapy program is designed to target senescence and age-associated disorders.

news

FDA approves COVID-19 treatment after successful use of STEM CELLS from RESTEM
May 14, 2020

CORONA, Calif., and MIAMI and SIOUX FALLS, S.D., May 14, 2020 — RESTEM, a leading cell-based therapeutics company, announced [...]

Patient Credits Stem Cell Treatment With Saving Her Life
May 8, 2020

MIAMI (CBSMiami) – The U.S. Food and Drug Administration gave Baptist Health approval to test a stem [...]

Florida Mom Recovers From Covid-19 with Stem Cell Therapy
May 8, 2020

A single mom in Florida’s sweet reunion with her two children was captured on video [...]

3 Miami COVID-19 Patients Successfully Recovered with Stem Cell Therapy
May 7, 2020

 A team of South Florida doctors have successfully treated three critically ill COVID-19 patients with [...]

COVID-19: Three Patients Successfully Treated with RESTEM Stem Cells
May 7, 2020

RESTEM, a leading-edge biotechnology company, and Baptist Health South Florida, today announced three COVID-19 patients with acute [...]

Restem
December 4, 2019

RESTEM to donate its proprietary ULSCs in an approved investigational new drug application phase I [...]

University of Murcia
September 1, 2019

University of Murcia, Spain commences preclinical umbilical cord lining stem cells (ULSCs) animal work on [...]

University of Murcia
July 18, 2019

University of Murcia, Spain completes preclinical umbilical cord lining stem cells (ULSCs) animal work illustrating [...]